AstraZeneca Swung to 2Q Net Loss But Raises Full-Year Revenue Guidance
29 Julio 2022 - 2:09AM
Noticias Dow Jones
By Ian Walker
AstraZeneca PLC on Friday reported a swing to second-quarter net
loss after booking a large foreign-exchange charge in its accounts,
but raised its full-year revenue guidance due to
better-than-expected Covid-19 medicine revenue.
The Anglo-Swedish pharma giant said it now expects to report a
low twenties percentage rise in total revenue for the year, up from
previous guidance of high teens percentage. It also said revenue
from Covid-19 medicines are expected to be flat compared with 2021.
It had previously guided for a low-to-mid twenties percentage
fall.
AstraZeneca posted a net loss of $372 million for the quarter
compared with a profit of $1.19 billion for the same period a year
earlier.
Revenue for the quarter rose to $10.77 billion, from $8.22
billion. Revenue consensus was $10.45 billion.
Core earnings per share--one of the company's preferred
metrics--rose to $1.72 in the quarter, compared with $0.90 and a
consensus of $1.57.
Consensus figures have been taken from FactSet and are based on
16 analysts' projections.
AstraZeneca reiterated that it expects core EPS growth in the
mid-to-high twenties percentage.
The board has increased its interim dividend to $0.93 a share
compared with $0.90 for the first half of 2021.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
July 29, 2022 02:54 ET (06:54 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024